Skip to main content

TIM3, UNA NUEVA Y PROMETEDORA DIANA INMUNOTERAPEUTICA EN LEUCEMIA LINFOBLASTICA AGUDA B DE NOVO Y EN RECAIDA

PID2019-108160RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 22
Encontrada(s) 1 página(s)

Docta Complutense
Publication Artículo científico (JournalArticle)

Engraftment characterization of risk-stratified AML in NSGS mice

  • Díaz de la Guardia, Rafael
  • Anguita Mandly, Eduardo Luis
  • Menéndez, Pablo
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Disease heterogeneity is well documented, and patient stratification determines treatment decisions. Patient-derived xenografts (PDXs) from risk-stratified AML are crucial for studying AML biology and testing novel therapeutics. Despite recent advances in PDX modeling of AML, reproducible engraftment of human AML is primarily limited to high-risk (HR) cases, with inconsistent or very protracted engraftment observed for favorable-risk (FR) and intermediate-risk (IR) patients. We used NSGS mice to characterize the engraftment robustness/kinetics of 28 AML patient samples grouped according to molecular/cytogenetic classification and assessed whether the orthotopic coadministration of patient-matched bone marrow mesenchymal stromal cells (BM MSCs) improves AML engraftment. PDX event-free survival correlated well with the predictable prognosis of risk-stratified AML patients. The majority (85-94%) of the mice were engrafted in bone marrow (BM) independently of the risk group, although HR AML patients showed engraftment levels that were significantly superior to those of FR or IR AML patients. Importantly, the engraftment levels observed in NSGS mice by week 6 remained stable over time. Serial transplantation and long-term culture-initiating cell (LTC-IC) assays revealed long-term engraftment limited to HR AML patients, fitter leukemia-initiating cells (LICs) in HR AML samples, and the presence of AML LICs in the CD34− leukemic fraction, regardless of the risk group. Finally, orthotopic coadministration of patient-matched BM MSCs and AML cells was dispensable for BM engraftment levels but favored peripheralization of engrafted AML cells. This comprehensive characterization of human AML engraftment in NSGS mice offers a valuable platform for in vivo testing of targeted therapies in risk-stratified AML patient samples.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia

  • Ramos-Muntada, Mireia
  • Trincado Alonso, Juan Luis, 1987-
  • Molina, Oscar
B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer. High hyperdiploidy (HHD) identifies the most frequent cytogenetic subgroup in childhood B-ALL. Although hyperdiploidy represents an important prognostic factor in childhood B-ALL, the specific chromosome gains with prognostic value in HHD-B-ALL remain controversial, and the current knowledge about the hierarchy of chromosome gains, clonal heterogeneity and chromosomal instability in HHD-B-ALL remains very limited. We applied automated sequential-iFISH coupled with single-cell computational modeling to identify the specific chromosomal gains of the eight typically gained chromosomes in a large cohort of 72 primary diagnostic (DX, n = 62) and matched relapse (REL, n = 10) samples from HHD-B-ALL patients with either favorable or unfavorable clinical outcome in order to characterize the clonal heterogeneity, specific chromosome gains and clonal evolution. Our data show a high degree of clonal heterogeneity and a hierarchical order of chromosome gains in DX samples of HHD-B-ALL. The rates of specific chromosome gains and clonal heterogeneity found in DX samples differ between HHD-B-ALL patients with favorable or unfavorable clinical outcome. In fact, our comprehensive analyses at DX using a computationally defined risk predictor revealed low levels of trisomies +18+10 and low levels of clonal heterogeneity as robust relapse risk factors in minimal residual disease (MRD)-negative childhood HHD-B-ALL patients: relapse-free survival beyond 5 years: 22.1% versus 87.9%, P < 0.0001 and 33.3% versus 80%, P < 0.0001, respectively. Moreover, longitudinal analysis of matched DX-REL HHD-B-ALL samples revealed distinct patterns of clonal evolution at relapse. Our study offers a reliable prognostic sub-stratification of pediatric MRD-negative HHD-B-ALL patients., This work is supported by the Spanish Ministry of Science and Innovation (PID2019-108160RB-I00/AEI/10.13039/501100011033, the European Research Council (CoG-2014-646903), the Spanish Ministry of Economy and Competitiveness (SAF2016-80481-R and SAF-2019-108160-R), the Leo Messi Foundation, the Health Institute Carlos III (ISCIII) (RICORS, RD21/0017/0029) within the Next Generation EU program (plan de recuperación, transformación y resilencia), and the Fundación Uno entre Cienmil (PM). Additional funding was provided by the ISCIII (FEDER PI17/01028 and PI20/00822) (CB), the Generalitat de Catalunya (2017/SGR-503) and the Universitat Autònoma de Barcelona (UAB/CF-180034) (JB) and the Blood Cancer UK (CJH). JLT was supported by a Juan de la Cierva fellowship by the Spanish Ministry of Science and Innovation (FJC2019-040868-I), BL-M was supported by the Asociación Española Contra el Cáncer (AECC; INVES20011LÓPE). AB was supported by the Fundación Española de Hematología y Hemoterapia (FEHH). OM was supported by a Beatriu de Pinós Postdoctoral Fellowship (BP2016-00048) from AGAUR (Generalitat de Catalunya), a 2017 Lady Tata Memorial Trust International Award, and the AECC (INVES211226MOLI). PM is an investigator of the Spanish Cell Therapy cooperative network (TERCEL).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells

  • Velasco Hernandez, Talia
  • Beneyto Calabuig, Sergi
  • Velten, Lars
  • Lorden, Patricia
  • Eyras Jiménez, Eduardo
  • Heyn, Holger
  • Menéndez, Pablo
Relapse remains a major challenge in the clinical management of acute myeloid leukemia (AML) and is driven by rare therapy-resistant leukemia stem cells (LSCs) that reside in specific bone marrow niches. Hypoxia signaling maintains cells in a quiescent and metabolically relaxed state, desensitizing them to chemotherapy. This suggests the hypothesis that hypoxia contributes to the chemoresistance of AML-LSCs and may represent a therapeutic target to sensitize AML-LSCs to chemotherapy. Here, we identify HIFhigh and HIFlow specific AML subgroups (inv(16)/t(8;21) and MLLr, respectively) and provide a comprehensive single-cell expression atlas of 119,000 AML cells and AML-LSCs in paired diagnostic-relapse samples from these molecular subgroups. The HIF/hypoxia pathway signature is attenuated in AML-LSCs compared with more differentiated AML cells but is more expressed than in healthy hematopoietic cells. Importantly, chemical inhibition of HIF cooperates with standard-of-care chemotherapy to impair AML growth and to substantially eliminate AML-LSCs in vitro and in vivo. These findings support the HIF pathway in the stem cell-driven drug resistance of AML and unravel avenues for combinatorial targeted and chemotherapy-based approaches to specifically eliminate AML-LSCs., This research was also supported by the Spanish Ministry of Economy and Competitiveness (SAF2016-80481R, PID2019-108160RB-I00/AEI/10.13039/50110011033), “la Caixa” Foundation (LCF/PR/HR19/52160011), the Leo Messi Foundation, “Heroes hasta la médula” initiative, Departament de Recerca i Universitats de la Generalitat de Catalunya (2021 SGR 00887) and ISCIII-RICORS within the Next Generation EU program (plan de recuperación, transformación y resiliencia) to PM and the Health Institute Carlos III (ISCIII/FEDER, PI20/00 822) to Clara Bueno.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression

  • López Millán, Belén
  • Valle Pérez, Beatriz del
  • García de Herreros, Antonio
  • Bueno, Clara
B-cell acute lymphoblastic leukemia (B-ALL) is the most common pediatric cancer, with long-term overall survival rates of ∼85%. However, B-ALL harboring rearrangements of the MLL gene (also known as KMT2A), referred to as MLLr B-ALL, is common in infants and is associated with poor 5-year survival, relapses, and refractoriness to glucocorticoids (GCs). GCs are an essential part of the treatment backbone for B-ALL, and GC resistance is a major clinical predictor of poor outcome. Elucidating the mechanisms of GC resistance in MLLr B-ALL is, therefore, critical to guide therapeutic strategies that deepen the response after induction therapy. Neuron-glial antigen-2 (NG2) expression is a hallmark of MLLr B-ALL and is minimally expressed in healthy hematopoietic cells. We recently reported that NG2 expression is associated with poor prognosis in MLLr B-ALL. Despite its contribution to MLLr B-ALL pathogenesis, the role of NG2 in MLLr-mediated leukemogenesis/chemoresistance remains elusive. Here, we show that NG2 is an epigenetically regulated direct target gene of the leukemic MLL-ALF transcription elongation factor 4 (AF4) fusion protein. NG2 negatively regulates the expression of the GC receptor nuclear receptor subfamily 3 group C member 1 (NR3C1) and confers GC resistance to MLLr B-ALL cells. Mechanistically, NG2 interacts with FLT3 to render ligand-independent activation of FLT3 signaling (a hallmark of MLLr B-ALL) and downregulation of NR3C1 via activating protein-1 (AP-1)-mediated transrepression. Collectively, our study elucidates the role of NG2 in GC resistance in MLLr B-ALL through FLT3/AP-1-mediated downregulation of NR3C1, providing novel therapeutic avenues for MLLr B-ALL., The authors thank CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, and the Cure2MLL project from the Fight Kids Cancer program of the European Science Foundation. Further financial support for this work was obtained from the Spanish Ministry of Economy and Competitiveness (PID2019-108160RB-I00 to P.M.), “Heroes hasta la médula” initiative and ISCIII-RICORS-TERAV within the Next Generation EU program (plan de recuperación, transformación y resiliencia), and the Health Institute Carlos III (ISCIII/FEDER, PI20/00822), the Asociación Española Contra el Cáncer, and the Fundación Unoentrecienmil to C.B. B.L.-M. was supported by the Asociación Española Contra el Cáncer (INVES20011LÓPE), Consejería de Salud y Familia (FEDER/PEER-0028-2020), and EMERGIA2021, funded by Consejería de Universidad, Investigación e Innovación, and by ERDF A way of making Europe. C.P. was supported by the Health Institute Carlos III (ISCIII/FEDER, FI21/00161). R.M. is supported by a grant from the DJCLS (07 R/2022).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice

  • Galindo-Campos, M. A.
  • Lutfi, Nuria
  • Bonnin, S.
  • Martínez, C.
  • Velasco-Hernández, Talia
  • García-Hernández, V.
  • Martín Caballero, Juan
  • Ampurdanés, Coral
  • Gimeno, R.
  • Colomo, L.
  • Roué, Gaël
  • Guilbaud, G.
  • Dantzer, Françoise
  • Navarro Medrano, Pilar
  • Murga, Matilde
  • Fernández-Capetillo, Óscar
  • Bigas, A.
  • Menéndez, Pablo
  • Sale; J. E.
Dysregulation of the c-Myc oncogene occurs in a wide variety of hematologic malignancies, and its overexpression has been linked with aggressive tumor progression. Here, we show that poly (ADP-ribose) polymerase 1 (PARP-1) and PARP-2 exert opposing influences on progression of c-Myc-driven B-cell lymphoma. PARP-1 and PARP-2 catalyze the synthesis and transfer of ADP-ribose units onto amino acid residues of acceptor proteins in response to DNA strand breaks, playing a central role in the response to DNA damage. Accordingly, PARP inhibitors have emerged as promising new cancer therapeutics. However, the inhibitors currently available for clinical use are not able to discriminate between individual PARP proteins. We found that genetic deletion of PARP-2 prevents c-Myc-driven B-cell lymphoma, whereas PARP-1 deficiency accelerates lymphomagenesis in the E¿-Myc mouse model of aggressive B-cell lymphoma. Loss of PARP-2 aggravates replication stress in preleukemic E¿-Myc B cells, resulting in accumulation of DNA damage and concomitant cell death that restricts the c-Myc-driven expansion of B cells, thereby providing protection against B-cell lymphoma. In contrast, PARP-1 deficiency induces a proinflammatory response and an increase in regulatory T cells, likely contributing to immune escape of B-cell lymphoma, resulting in an acceleration of lymphomagenesis. These findings pinpoint specific functions for PARP-1 and PARP-2 in c-Myc-driven lymphomagenesis with antagonistic consequences that may help inform the design of new PARP-centered therapeutic strategies, with selective PARP-2 inhibition potentially representing a new therapeutic approach for the treatment of c-Myc-driven tumors., The J.Y. laboratory is funded by the Spanish Ministerio de Economía, Industria y Competitividad (grant SAF2017-83565-R), Spanish Ministerio de Ciencia e Innovación (grant PID2020-112526RB-I00), and Fundación Científica de la Asociación Española Contra el Cáncer (grant PROYEI6018YÉLA). Work in the J.E.S. laboratory is supported by a core grant to the Laboratory of Molecular Biology from the Medical Research Council (U105178808). The F.D. laboratory is supported by a Laboratory of Excellence grant (ANR-10-LABX-0034_Medalis) to Strasbourg University, Centre National de la Recherche Scientifique. The P.N. laboratory is supported by grants from the Spanish Ministry of Economy and Competitiveness/Instituto de Salud Carlos III–Fondo Europeo de Desarrollo Regional (FEDER; PI17/00199 and PI20/00625) and the Generalitat de Catalunya (2017-SGR-225). The P.M. laboratory acknowledges support from Centres de Recerca de Catalunya/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the Spanish Ministry of Economy and Competitiveness (grant SAF-2019-108160-R), the Fundación Uno entre Cienmil, the Obra Social La Caixa (grant LCF/PR/HR19/52160011), and the German Josep Carreras Leukamie Stiftung. Work at the G.R. and P.M. laboratories are cofinanced by the European Regional Development Fund through the Interreg V-A Spain-France-Andorra Program (project PROTEOblood; grant EFA360/19). The O.F.-C. laboratory is funded by grants from the Spanish Ministry of Science, Innovation and Universities (RTI2018-102204-B-I00; cofinanced with European FEDER funds) and the European Research Council (ERC-617840). T.V.-H. was supported by a Marie Sklodowska Curie fellowship (GA792923). The A.B. laboratory is supported by the Spanish Ministry of Economy and Competitiveness (grant PID2019-104695RB-I00)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

CD34+CD19−CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

  • Bueno, Clara
  • Barrera, Susana
  • Bataller, Alex
  • Ortiz-Maldonado, Valentín
  • Elliot, Natalina
  • O’Byrne, Sorcha
  • Wang, Guanlin
  • Rovira, Montserrat
  • Gutierrez-Aguera, Francisco
  • Trincado, Juan L.
  • González-González, María
  • Morgades, Mireia
  • Sorigué, Marc
  • Bárcena, Paloma
  • Zanetti, Samanta Romina
  • Torrebadell, Montse
  • Vega-García, Nerea
  • Rives, Susana
  • Mallo, Mar
  • Solé, Francesc
  • Mead, Adam J.
  • Roberts, Irene
  • Thongjuea, Supat
  • Psaila, Bethan
  • Juan, Manel
  • Delgado, Julio
  • Urbano-Ispizúa, Álvaro
  • Ribera, Josep-Maria
  • Orfao, Alberto
  • Roy, Anindita
  • Menéndez, Pablo
CD19-directed immunotherapies have revolutionized the treatment of advanced B-cell acute lymphoblastic leukemia (B-ALL). Despite initial impressive rates of complete remission (CR) many patients ultimately relapse. Patients with B-ALL successfully treated with CD19-directed T cells eventually relapse, which, coupled with the early onset of CD22 expression during B-cell development, suggests that preexisting CD34+CD22+CD19− (pre)-leukemic cells represent an “early progenitor origin-related” mechanism underlying phenotypic escape to CD19-directed immunotherapies. We demonstrate that CD22 expression precedes CD19 expression during B-cell development. CD34+CD19−CD22+ cells are found in diagnostic and relapsed bone marrow samples of ∼70% of patients with B-ALL, and their frequency increases twofold in patients with B-ALL in CR after CD19 CAR T-cell therapy. The median of CD34+CD19−CD22+ cells before treatment was threefold higher in patients in whom B-ALL relapsed after CD19-directed immunotherapy (median follow-up, 24 months). Fluorescence in situ hybridization analysis in flow-sorted cell populations and xenograft modeling revealed that CD34+CD19−CD22+ cells harbor the genetic abnormalities present at diagnosis and initiate leukemogenesis in vivo. Our data suggest that preleukemic CD34+CD19−CD22+ progenitors underlie phenotypic escape after CD19-directed immunotherapies and reinforce ongoing clinical studies aimed at CD19/CD22 dual targeting as a strategy for reducing CD19− relapses. The implementation of CD34/CD19/CD22 immunophenotyping in clinical laboratories for initial diagnosis and subsequent monitoring of patients with B-ALL during CD19-targeted therapy is encouraged., The work in P.M. and C.B.’s Laboratory was supported by the European Research Council (CoG-2014-646903, PoC-2018-811220) and the Spanish Ministry of Economy and Competitiveness (SAF2016-80481R, PID2019-108160RB-I00) (P.M.); the ISCIII (ISCIII/FEDER, PI17/01028 and PI20/00822), the Spanish Association against Cancer (AECC), and the FERO Foundation (C.B.). P.M. and J.M.R. acknowledge the support of ISCIII-RICORS within the Next Generation EU program (Plan de Recuperación, Transformación y Resiliencia). N.E. is supported by Cancer Research UK and a Children and Young People’s Cancer Innovation Award (DRCPGM\100058). A.R. is supported by a Wellcome Trust Clinical Research Career Development Fellowship (216632/Z/19/Z). A.O. was supported by ISCIII (PI19/011183). F.S. was supported by AGAUR/Generalitat de Catalunya (SGR288). The single-cell transcriptomic analysis was supported by MRC Discovery award MRCDA 0816-11 and the MRC WIMM Single Cell Facility and MRC-funded Oxford Consortium for Single-Cell Biology (MR/M00919X/1) provided assistance., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo

  • Díez-Alonso, Laura
  • Falgàs, Aïda
  • Arroyo-Ródenas, Javier
  • Romencín, Paola A
  • Martínez, Alba
  • Gómez-Rosel, Marina
  • Blanco, Belén
  • Jiménez-Reinoso, Anaïs
  • Mayado, Andrea
  • Pérez-Pons, Alba
  • Aguilar-Sopeña, Óscar
  • Ramírez-Fernández, Ángel
  • Segura-Tudela, Alejandro
  • Perez-Amill, Lorena
  • Tapia-Galisteo, Antonio
  • Domínguez-Alonso, Carmen
  • Rubio-Pérez, Laura
  • Jara-Acevedo, Maria
  • Solé, Francesc
  • Hangiu, Oana
  • Almagro, Laura
  • Albitre, Ángela
  • Penela, Petronila
  • Sanz, Laura
  • Anguita, Eduardo
  • Valeri, Antonio
  • García-Ortiz, Almudena
  • Río, Paula
  • Juan, Manel
  • Martínez-López, Joaquín
  • Roda-Navarro, Pedro
  • Martin-Antonio, Beatriz
  • Orfao, Alberto
  • Menéndez, Pablo
  • Bueno, Clara
  • Álvarez-Vallina, Luis
Multiple myeloma is the second most common hematological malignancy in adults and remains an incurable disease. B cell maturation antigen (BCMA)–directed immunotherapy, including T cells bearing chimeric antigen receptors (CARs) and systemically injected bispecific T cell engagers (TCEs), has shown remarkable clinical activity, and several products have received market approval. However, despite promising results, most patients eventually become refractory and relapse, highlighting the need for alternative strategies. Engineered T cells secreting TCE antibodies (STAb) represent a promising strategy that combines the advantages of adoptive cell therapies and bispecific antibodies. Here, we undertook a comprehensive preclinical study comparing the therapeutic potential of T cells either expressing second-generation anti-BCMA CARs (CAR-T) or secreting BCMAxCD3 TCEs (STAb-T) in a T cell–limiting experimental setting mimicking the conditions found in patients with relapsed/refractory multiple myeloma. STAb-T cells recruited T cell activity at extremely low effector-to-target ratios and were resistant to inhibition mediated by soluble BCMA released from the cell surface, resulting in enhanced cytotoxic responses and prevention of immune escape of multiple myeloma cells in vitro. These advantages led to robust expansion and persistence of STAb-T cells in vivo, generating long-lived memory BCMA-specific responses that could control multiple myeloma progression in xenograft models, outperforming traditional CAR-T cells. These promising preclinical results encourage clinical testing of the BCMA-STAb-T cell approach in relapsed/refractory multiple myeloma., Financial support for this work was obtained from the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033 (PID2020-115444GB-I00 to P.R.-N., PID2019-108160RB-I00 to P.M., PLE2021-0075 to C.B., and PID2020-117323RB-100 and PDC2021-121711-100 to L.Á.-V.), partially supported by the European Regional Development Fund (ERDF); the Carlos III Health Institute (ISCIII) (PI20/01030 to B.B., PI19/00132 to L.S., PI21-01834 to P.P., PI20/00822 to C.B., and DTS20/00089 to L.Á.-V.), partially supported by the ERDF; the ISCIII-RICORS within the Next Generation EU program (plan de Recuperación, Transformación y Resilencia) (RD21/0017/0030 to B.B. and J.M.-L. and RD21/0017/0029 to P.M.); the ISCIII-CIBERONC program (CB16/12/00400 to A.O.), the CRIS Cancer Foundation (FCRIS-2021-001 to J.M.-L. and FCRIS-2021-0090 to L.Á.-V.), the Spanish Association Against Cancer (AECC) (PRYGN234975MENE to P.M., PRYGN211192BUEN to C.B., and PROYE19084ALVA and PRYGN234844ALVA to L.Á.-V.); the Accelerator Award-Cancer Research UK/AIRC/AECC-INCAR (GEACC18001ORF to A.O.), the Fundación “La Caixa” (LCF/PR/HR19/52160011 to P.M. and HR21-00761 project IL7R_LungCan to L.Á.-V.), the European Research Council (ERC) (ERC-PoC-957466 to P.M.) and ERC under the EU’s Horizon Program (grant agreement 101100665 to P.M.), the Fundación de Investigación Biomédica 12 de Octubre (programa Investiga 2022-0082) to L.Á.-V.; the Fundación Ramón Areces to P.P. L.D.-A. was supported by a Rio Hortega fellowship from the Carlos III Health Institute (CM20/00004). A.F. was supported by a postdoctoral fellowship from the Spanish Ministry of Science and Innovation (FJC2021-046789-I). A. Mayado was supported by the CIBERONC (PRF-2869). A.P.-P. was supported by a grant from the Government of Castilla y León (Orden EDU/556/2019; Valladolid, Spain). M.G.-R. was supported by an industrial PhD fellowship from the Comunidad de Madrid (IND2022/BMD-23732). O.A.-S. was supported by a PhD fellowship from the Complutense University of Madrid. C.D.-A. was supported by a PhD fellowship from the Spanish Ministry of Science and Innovation (PRE2018-083445). L.R.-P. was supported by a PhD fellowship from the Immunology Chair, Universidad Francisco de Vitoria/Merck. O.H. was supported by an industrial PhD fellowship from the Comunidad de Madrid (IND2020/BMD-17668). A.V. is supported by Research Institute Hospital 12 de Octubre (imas12). A.G.-O. is supported by HIGEA 2019/0123 AIE project to J.M.-L., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers

  • Jiménez-Reinoso, Anaïs
  • Tirado, Néstor
  • Martinez-Moreno, Alba
  • Díaz, Víctor M
  • García-Peydró, Marina
  • Hangiu, Oana
  • Díez-Alonso, Laura
  • Albitre, Ángela
  • Penela, Petronila
  • Álvarez-Vallina, Luis
  • Sánchez Martínez, Diego
BACKGROUND: The dismal clinical outcome of relapsed/refractory (R/R) T cell acute lymphoblastic leukemia (T-ALL) highlights the need for innovative targeted therapies. Although chimeric antigen receptor (CAR)-engineered T cells have revolutionized the treatment of B cell malignancies, their clinical implementation in T-ALL is in its infancy. CD1a represents a safe target for cortical T-ALL (coT-ALL) patients, and fratricide-resistant CD1a-directed CAR T cells have been preclinically validated as an immunotherapeutic strategy for R/R coT-ALL. Nonetheless, T-ALL relapses are commonly very aggressive and hyperleukocytic, posing a challenge to recover sufficient non-leukemic effector T cells from leukapheresis in R/R T-ALL patients. METHODS: We carried out a comprehensive study using robust in vitro and in vivo assays comparing the efficacy of engineered T cells either expressing a second-generation CD1a-CAR or secreting CD1a x CD3 T cell-engaging Antibodies (CD1a-STAb). RESULTS: We show that CD1a-T cell engagers bind to cell surface expressed CD1a and CD3 and induce specific T cell activation. Recruitment of bystander T cells endows CD1a-STAbs with an enhanced in vitro cytotoxicity than CD1a-CAR T cells at lower effector:target ratios. CD1a-STAb T cells are as effective as CD1a-CAR T cells in cutting-edge in vivo T-ALL patient-derived xenograft models. CONCLUSIONS: Our data suggest that CD1a-STAb T cells could be an alternative to CD1a-CAR T cells in coT-ALL patients with aggressive and hyperleukocytic relapses with limited numbers of non-leukemic effector T cells., Research in LA-V laboratory is funded by the Spanish Ministry of Science and Innovation (PID2020-117323RB-100 and PDC2021-121711-100), and the Carlos III Health Institute (DTS20/00089), with European Regional Development Fund (FEDER) cofinancing; the Spanish Association Against Cancer (AECC PROYE19084ALVA) and the CRIS Cancer Foundation (FCRIS-2018-0042 and FCRIS-2021-0090). Research in PM laboratory is supported by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support; 'la Caixa' Foundation under the agreement LCF/PR/HR19/52160011; the European Research Council grant (ERC-PoC-957466); the Spanish Ministry of Science and Innovation (PID2019-108160RB-I00); and the ISCIII-RICORS within the Next Generation EU program (plan de Recuperación, Transformación y Resilencia). MLT is supported by Spanish Ministry of Science and Innovation (PID2019-105623RB-I00) and the Spanish Association Against Cancer (CICPF18030TORI). PP is supported by Carlos III Health Institute (PI21-01834), with FEDER cofinancing and Fundación Ramón Areces. NT was supported by an FPU PhD fellowship from Spain's Ministerio de Universidades (FPU19/00039). OH was supported by an industrial PhD fellowship from the Comunidad de Madrid (IND2020/BMD-17668). LD-A was supported by a Rio Hortega fellowship from the Carlos III Health Institute (CM20/00004). VMD is supported by the Torres Quevedo subprogram of the State Research Agency of the Ministry of Science, Innovation and Universities (Ref. PTQ2020-011056). DSM is partially founded by a Sara Borrell fellowship from Carlos III Health Institute (CD19/00013).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression

  • Lopez-Millan, Belén
  • Fraga, Mario F.
  • Tejedor, Juan Ramón
  • Menéndez, Pablo
  • Bueno, Clara
et al., Referred to by: NG2 at the core: tackling MLLr B-ALL resistance. Blood, Volume 144, Issue 19, 7 November 2024, Pages 1977-1978. Duohui Jing, B-cell acute lymphoblastic leukemia (B-ALL) is the most common pediatric cancer, with long-term overall survival rates of ∼85%. However, B-ALL harboring rearrangements of the MLL gene (also known as KMT2A), referred to as MLLr B-ALL, is common in infants and is associated with poor 5-year survival, relapses, and refractoriness to glucocorticoids (GCs). GCs are an essential part of the treatment backbone for B-ALL, and GC resistance is a major clinical predictor of poor outcome. Elucidating the mechanisms of GC resistance in MLLr B-ALL is, therefore, critical to guide therapeutic strategies that deepen the response after induction therapy. Neuron-glial antigen-2 (NG2) expression is a hallmark of MLLr B-ALL and is minimally expressed in healthy hematopoietic cells. We recently reported that NG2 expression is associated with poor prognosis in MLLr B-ALL. Despite its contribution to MLLr B-ALL pathogenesis, the role of NG2 in MLLr-mediated leukemogenesis/chemoresistance remains elusive. Here, we show that NG2 is an epigenetically regulated direct target gene of the leukemic MLL-ALF transcription elongation factor 4 (AF4) fusion protein. NG2 negatively regulates the expression of the GC receptor nuclear receptor subfamily 3 group C member 1 (NR3C1) and confers GC resistance to MLLr B-ALL cells. Mechanistically, NG2 interacts with FLT3 to render ligand-independent activation of FLT3 signaling (a hallmark of MLLr B-ALL) and downregulation of NR3C1 via activating protein-1 (AP-1)–mediated transrepression. Collectively, our study elucidates the role of NG2 in GC resistance in MLLr B-ALL through FLT3/AP-1–mediated downregulation of NR3C1, providing novel therapeutic avenues for MLLr B-ALL., The authors thank CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, and the Cure2MLL project from the Fight Kids Cancer program of the European Science Foundation. Further financial support for this work was obtained from the Spanish Ministry of Economy and Competitiveness (PID2019-108160RB-I00 to P.M.), “Heroes hasta la médula” initiative and ISCIII-RICORS-TERAV within the Next Generation EU program (plan de recuperación, transformación y resiliencia), and the Health Institute Carlos III (ISCIII/FEDER, PI20/00822), the Asociación Española Contra el Cáncer, and the Fundación Unoentrecienmil to C.B. B.L.-M. was supported by the Asociación Española Contra el Cáncer (INVES20011LÓPE), Consejería de Salud y Familia (FEDER/PEER-0028-2020), and EMERGIA2021, funded by Consejería de Universidad, Investigación e Innovación, and by ERDF A way of making Europe. C.P. was supported by the Health Institute Carlos III (ISCIII/FEDER, FI21/00161). R.M. is supported by a grant from the DJCLS (07 R/2022)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A TIM-3–Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia

  • Falgàs, Aïda
  • Lázaro-Gorines, Rodrigo
  • Zanetti, Samanta Romina
  • Rubio-Pérez, Laura
  • Martínez-Moreno, Alba
  • Vinyoles, Meritxell
  • Guerrero-Murillo, Mercedes
  • Fernández-Fuentes, Narcís
  • Roca-Ho, Heleia
  • Tirado, Néstor
  • Panisello, Carla
  • Velasco-Hernández, Talia
  • Mayado, Andrea
  • Pérez-Pons, Alba
  • Genescà, Eulàlia
  • Ribera, Josep-Maria
  • Ribera, Jordi
  • Camós, Mireia
  • Ramírez-Orellana, Manuel
  • Anguita, Eduardo
  • Ballerini, Paola
  • Fuster, José Luis
  • Juan, Manel
  • González-Navarro, Azucena
  • Locatelli, Franco
  • Stam, Ronald W.
  • Querol, Sergi
  • Velasco, Pablo
  • Ortiz-Maldonado, Valentín
  • Martínez-Cibrián, Nuria
  • Delgado, Julio
  • Orfao, Alberto
  • Álvarez-Vallina, Luis
  • Bueno, Clara
  • Menéndez, Pablo
Relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remains a challenging disease with dismal prognosis. Despite the revolutionary impact of CD19-directed chimeric antigen receptor (CAR19) T-cell therapy, >50% of patients relapse within a year. Both leukemia cell–intrinsic factors favoring immune escape and poor CAR T-cell persistence contribute to clinical failure. Moreover, the expression of immune checkpoint receptors (ICRs) and their ligands within the bone marrow (BM) microenvironment may contribute to leukemia progression and therapy resistance. Here, we characterized the expression of ICRs and their ligands in leukemic blasts, T cells, and mesenchymal stromal cells (MSCs) from B-ALL BM samples at diagnosis and relapse, comparing them with age-matched healthy BM controls. Our findings reveal a significantly upregulated expression of TIM-3 in T cells and its ligand, galectin-9, in both blasts and MSCs throughout disease progression. The expression of galectin-9 in B-ALL blasts and TIM-3 in CAR19 T cells negatively correlates with clinical outcome. Furthermore, we demonstrate that galectin-9 impairs CAR19 T-cell homeostasis and cytotoxicity. Notably, an engineered TIM-3–Fc decoy receptor, delivered either by primary T cells coadministered with CAR19 T cells or via a bicistronic all-in-one CAR19–TIM-3–Fc construct, improved the antileukemia efficacy and persistence of CAR19 T cells in B-ALL xenograft models. Mechanistically, CAR19–TIM-3–Fc T-cell treatment promotes the in vivo expansion of transduced and bystander effector and memory T cells, as determined by spectral flow cytometry. Collectively, these TIM-3–Fc decoy–armored CAR19 T cells offer a promising therapeutic strategy for patients with R/R B-ALL., Samples included in this study were provided by the collection of samples of the Josep Carreras Leukemia Research Institute (C002922) and were processed following standard operating procedures with the appropriate approval of the Ethics and Scientific Committees. Core support of research in the P.M. laboratory is provided by CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa; additional support is provided by the European Research Council (grants ERC-PoC-957466 IT4B-TALL and ERC-PoC-101100665 BiTE-CAR); Horizon 2020 (grant 101057250-CANCERNA), the Ministerio de Economía, Industria y Competitividad (MINECO; grants PID2019-108160RB-I00 and PID2022-142966OB-I00/MCIN/AEI/10.13039/501100011033 and Feder Funds), MINECO/European Union NextGenerationEU (grants CPP2021-008508 and CPP2022-009759); the Spanish Association Against Cancer (AECC; grants PRYGN234975MENE, and PRYGN211192BUEN), the Health Institute Carlos III (ISCIII; grant PI20/00822), the Uno Entre Cien Mil Foundation, Dutch Josep Carreras Leukemia Stifftung (DJCLS; grant 02 R/2023), MINECO (grant PLE2021-007518), and the ISCIII-RICORS within the Next Generation EU program (plan de Recuperación, Transformación y Resilencia). Research in the L.Á.-V. laboratory is funded by the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/ 501100011033 (grants PID2023-148429OB-I00, PID2020-117323RB-I00, PDC2021-121711-100, CPP2022-009762, and CPP2022-009765); the ISCIII/FEDER (grants DTS20/00089 and PMPTA22/00167), the AECC (grants PROYE19084ALVA and PRYGN234844ALVA); the CRIS Cancer Foundation, Spain (grants FCRIS-2021-0090 and FCRIS-2023-0070); the Fundación “La Caixa” (grant HR21-00761 project IL7R_LungCan); the Comunidad de Madrid (grant P2022/BMD-7225 Next Generation CART MAD), and the Fundación d'Estudis i Recerca Oncológica (BBASELGAFERO2024.01). A.F. was supported by a Juan de la Cierva postdoctoral fellowship (FJC2021-046789-I); N.T. was supported by a PhD fellowship (FPU19/00039) from the Spanish Ministry of Science and Innovation; and C.P. was supported by a Contratos predoctorales de formación en investigación en salud fellowship (FI21/00161) from ISCIII. L.R.-P. is supported by a predoctoral fellowship from the Immunology Chair, Universidad Francisco de Vitoria/Merck. S.R.Z. was supported by a Marie Sklodowska Curie Fellowship (GA 795833)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia

  • Ramos-Muntada, Mireia
  • Trincado Alonso, Juan Luis, 1987-
  • Molina, Oscar
B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer. High hyperdiploidy (HHD) identifies the most frequent cytogenetic subgroup in childhood B-ALL. Although hyperdiploidy represents an important prognostic factor in childhood B-ALL, the specific chromosome gains with prognostic value in HHD-B-ALL remain controversial, and the current knowledge about the hierarchy of chromosome gains, clonal heterogeneity and chromosomal instability in HHD-B-ALL remains very limited. We applied automated sequential-iFISH coupled with single-cell computational modeling to identify the specific chromosomal gains of the eight typically gained chromosomes in a large cohort of 72 primary diagnostic (DX, n = 62) and matched relapse (REL, n = 10) samples from HHD-B-ALL patients with either favorable or unfavorable clinical outcome in order to characterize the clonal heterogeneity, specific chromosome gains and clonal evolution. Our data show a high degree of clonal heterogeneity and a hierarchical order of chromosome gains in DX samples of HHD-B-ALL. The rates of specific chromosome gains and clonal heterogeneity found in DX samples differ between HHD-B-ALL patients with favorable or unfavorable clinical outcome. In fact, our comprehensive analyses at DX using a computationally defined risk predictor revealed low levels of trisomies +18+10 and low levels of clonal heterogeneity as robust relapse risk factors in minimal residual disease (MRD)-negative childhood HHD-B-ALL patients: relapse-free survival beyond 5 years: 22.1% versus 87.9%, P < 0.0001 and 33.3% versus 80%, P < 0.0001, respectively. Moreover, longitudinal analysis of matched DX-REL HHD-B-ALL samples revealed distinct patterns of clonal evolution at relapse. Our study offers a reliable prognostic sub-stratification of pediatric MRD-negative HHD-B-ALL patients., This work is supported by the Spanish Ministry of Science and Innovation (PID2019-108160RB-I00/AEI/10.13039/501100011033, the European Research Council (CoG-2014-646903), the Spanish Ministry of Economy and Competitiveness (SAF2016-80481-R and SAF-2019-108160-R), the Leo Messi Foundation, the Health Institute Carlos III (ISCIII) (RICORS, RD21/0017/0029) within the Next Generation EU program (plan de recuperación, transformación y resilencia), and the Fundación Uno entre Cienmil (PM). Additional funding was provided by the ISCIII (FEDER PI17/01028 and PI20/00822) (CB), the Generalitat de Catalunya (2017/SGR-503) and the Universitat Autònoma de Barcelona (UAB/CF-180034) (JB) and the Blood Cancer UK (CJH). JLT was supported by a Juan de la Cierva fellowship by the Spanish Ministry of Science and Innovation (FJC2019-040868-I), BL-M was supported by the Asociación Española Contra el Cáncer (AECC; INVES20011LÓPE). AB was supported by the Fundación Española de Hematología y Hemoterapia (FEHH). OM was supported by a Beatriu de Pinós Postdoctoral Fellowship (BP2016-00048) from AGAUR (Generalitat de Catalunya), a 2017 Lady Tata Memorial Trust International Award, and the AECC (INVES211226MOLI). PM is an investigator of the Spanish Cell Therapy cooperative network (TERCEL).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells

  • Velasco Hernandez, Talia
  • Beneyto Calabuig, Sergi
  • Velten, Lars
  • Lorden, Patricia
  • Eyras Jiménez, Eduardo
  • Heyn, Holger
  • Menéndez, Pablo
Relapse remains a major challenge in the clinical management of acute myeloid leukemia (AML) and is driven by rare therapy-resistant leukemia stem cells (LSCs) that reside in specific bone marrow niches. Hypoxia signaling maintains cells in a quiescent and metabolically relaxed state, desensitizing them to chemotherapy. This suggests the hypothesis that hypoxia contributes to the chemoresistance of AML-LSCs and may represent a therapeutic target to sensitize AML-LSCs to chemotherapy. Here, we identify HIFhigh and HIFlow specific AML subgroups (inv(16)/t(8;21) and MLLr, respectively) and provide a comprehensive single-cell expression atlas of 119,000 AML cells and AML-LSCs in paired diagnostic-relapse samples from these molecular subgroups. The HIF/hypoxia pathway signature is attenuated in AML-LSCs compared with more differentiated AML cells but is more expressed than in healthy hematopoietic cells. Importantly, chemical inhibition of HIF cooperates with standard-of-care chemotherapy to impair AML growth and to substantially eliminate AML-LSCs in vitro and in vivo. These findings support the HIF pathway in the stem cell-driven drug resistance of AML and unravel avenues for combinatorial targeted and chemotherapy-based approaches to specifically eliminate AML-LSCs., This research was also supported by the Spanish Ministry of Economy and Competitiveness (SAF2016-80481R, PID2019-108160RB-I00/AEI/10.13039/50110011033), “la Caixa” Foundation (LCF/PR/HR19/52160011), the Leo Messi Foundation, “Heroes hasta la médula” initiative, Departament de Recerca i Universitats de la Generalitat de Catalunya (2021 SGR 00887) and ISCIII-RICORS within the Next Generation EU program (plan de recuperación, transformación y resiliencia) to PM and the Health Institute Carlos III (ISCIII/FEDER, PI20/00 822) to Clara Bueno.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression

  • López Millán, Belén
  • Valle Pérez, Beatriz del
  • García de Herreros, Antonio
  • Bueno, Clara
B-cell acute lymphoblastic leukemia (B-ALL) is the most common pediatric cancer, with long-term overall survival rates of ∼85%. However, B-ALL harboring rearrangements of the MLL gene (also known as KMT2A), referred to as MLLr B-ALL, is common in infants and is associated with poor 5-year survival, relapses, and refractoriness to glucocorticoids (GCs). GCs are an essential part of the treatment backbone for B-ALL, and GC resistance is a major clinical predictor of poor outcome. Elucidating the mechanisms of GC resistance in MLLr B-ALL is, therefore, critical to guide therapeutic strategies that deepen the response after induction therapy. Neuron-glial antigen-2 (NG2) expression is a hallmark of MLLr B-ALL and is minimally expressed in healthy hematopoietic cells. We recently reported that NG2 expression is associated with poor prognosis in MLLr B-ALL. Despite its contribution to MLLr B-ALL pathogenesis, the role of NG2 in MLLr-mediated leukemogenesis/chemoresistance remains elusive. Here, we show that NG2 is an epigenetically regulated direct target gene of the leukemic MLL-ALF transcription elongation factor 4 (AF4) fusion protein. NG2 negatively regulates the expression of the GC receptor nuclear receptor subfamily 3 group C member 1 (NR3C1) and confers GC resistance to MLLr B-ALL cells. Mechanistically, NG2 interacts with FLT3 to render ligand-independent activation of FLT3 signaling (a hallmark of MLLr B-ALL) and downregulation of NR3C1 via activating protein-1 (AP-1)-mediated transrepression. Collectively, our study elucidates the role of NG2 in GC resistance in MLLr B-ALL through FLT3/AP-1-mediated downregulation of NR3C1, providing novel therapeutic avenues for MLLr B-ALL., The authors thank CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, and the Cure2MLL project from the Fight Kids Cancer program of the European Science Foundation. Further financial support for this work was obtained from the Spanish Ministry of Economy and Competitiveness (PID2019-108160RB-I00 to P.M.), “Heroes hasta la médula” initiative and ISCIII-RICORS-TERAV within the Next Generation EU program (plan de recuperación, transformación y resiliencia), and the Health Institute Carlos III (ISCIII/FEDER, PI20/00822), the Asociación Española Contra el Cáncer, and the Fundación Unoentrecienmil to C.B. B.L.-M. was supported by the Asociación Española Contra el Cáncer (INVES20011LÓPE), Consejería de Salud y Familia (FEDER/PEER-0028-2020), and EMERGIA2021, funded by Consejería de Universidad, Investigación e Innovación, and by ERDF A way of making Europe. C.P. was supported by the Health Institute Carlos III (ISCIII/FEDER, FI21/00161). R.M. is supported by a grant from the DJCLS (07 R/2022).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Aneuploidy in Cancer, Lessons from Acute Lymphoblastic Leukemia

  • Molina, Oscar|||0000-0001-7585-4519
  • Abad, Maria Alba|||0000-0002-8816-1524
  • Sole, F.|||0000-0002-3251-2161
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Aneuploidy, the gain or loss of chromosomes in a cell, is a hallmark of cancer. Although our understanding of the contribution of aneuploidy to cancer initiation and progression is incomplete, significant progress has been made in uncovering the cellular consequences of aneuploidy and how aneuploid cancer cells self-adapt to promote tumorigenesis. Aneuploidy is physiologically associated with significant cellular stress but, paradoxically, it favors tumor progression. Although more common in solid tumors, different forms of aneuploidy represent the initiating oncogenic lesion in patients with B cell acute lymphoblastic leukemia (B-ALL), making B-ALL an excellent model for studying the role of aneuploidy in tumorigenesis. We review the molecular mechanisms underlying aneuploidy and discuss its contributions to B-ALL initiation and progression.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Near-Haploidy and Low-Hypodiploidy in B-Cell Acute Lymphoblastic Leukemia, When Less Is Too Much

  • Molina, Oscar|||0000-0001-7585-4519
  • Bataller, Alex|||0000-0002-6085-2745
  • Thampi, Namitha|||0000-0001-6166-583X
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Granada, Isabel|||0000-0002-4275-0104
  • Velasco Puyo, Pablo|||0000-0001-7331-9483
  • Fuster, José Luis|||0000-0002-4881-9440
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
B-cell acute lymphoblastic leukemia (B-ALL) is characterized by an uncontrolled proliferation of blood cells in the bone marrow. A small fraction of B-ALL patients shows abnormally low chromosome numbers, defined as hypodiploidy, in leukemic cells. Hypodiploidy with less than 40 chromosomes is a rare genetic abnormality in B-ALL and is associated to an extremely poor outcome, with low survival rates both in pediatric and adult cases. In this review, we describe the main clinical and genetic features of hypodiploid B-ALL subtypes with less than 40 chromosomes, the current treatment protocols and their clinical outcomes. Additionally, we discuss the potential cellular mechanisms involved on the origin of hypodiploidy, as well as its leukemogenic impact. Studies aiming to decipher the biological mechanisms involved in hypodiploid subtypes of B-ALL with less than 40 chromosomes are crucial to improve the poor survival rates in these patients. Hypodiploidy with less than 40 chromosomes is a rare genetic abnormality in B-cell acute lymphoblastic leukemia (B-ALL). This condition can be classified based on modal chromosome number as low-hypodiploidy (30-39 chromosomes) and near-haploidy (24-29 chromosomes), with unique cytogenetic and mutational landscapes. Hypodiploid B-ALL with <40 chromosomes has an extremely poor outcome, with 5-year overall survival rates below 50% and 20% in childhood and adult B-ALL, respectively. Accordingly, this genetic feature represents an adverse prognostic factor in B-ALL and is associated with early relapse and therapy refractoriness. Notably, half of all patients with hypodiploid B-ALL with <40 chromosomes cases ultimately exhibit chromosome doubling of the hypodiploid clone, resulting in clones with 50-78 chromosomes. Doubled clones are often the major clones at diagnosis, leading to "masked hypodiploidy", which is clinically challenging as patients can be erroneously classified as hyperdiploid B-ALL. Here, we summarize the main cytogenetic and molecular features of hypodiploid B-ALL subtypes, and provide a brief overview of the diagnostic methods, standard-of-care treatments and overall clinical outcome. Finally, we discuss molecular mechanisms that may underlie the origin and leukemogenic impact of hypodiploidy and may open new therapeutic avenues to improve survival rates in these patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia

  • Ramos-Muntada, Mireia|||0000-0002-5531-1442
  • Trincado Alonso, Juan Luis, 1987-|||0000-0001-5363-3774
  • Blanco, Joan|||0000-0003-0647-3856
  • Bueno, Clara|||0000-0003-1442-6216
  • Rodríguez-Cortez, Virginia Carolina|||0000-0002-0853-247X
  • Bataller, Alex|||0000-0002-6085-2745
  • López-Millán, Belén|||0000-0002-9757-5454
  • Schwab, Claire
  • Ortega, Margarita
  • Velasco Puyo, Pablo|||0000-0001-7331-9483
  • Blanco, María L.
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Minguela, Alfredo|||0000-0003-2472-5893
  • Fuster, José Luis|||0000-0002-4881-9440
  • Cuatrecasas, Esther|||0000-0003-2881-4412
  • Camós, Mireia|||0000-0003-3658-7942
  • Ballerini, Paola
  • Escherich, Gabriele
  • Boer, Judith
  • DenBoer, Monique
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
  • Calasanz, M.J.|||0000-0002-0374-3008
  • Cazzaniga, Giovanni|||0000-0003-2955-4528
  • Harrison, Christine J.
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Molina, Oscar|||0000-0001-7585-4519
B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer. High hyperdiploidy (HHD) identifies the most frequent cytogenetic subgroup in childhood B-ALL. Although hyperdiploidy represents an important prognostic factor in childhood B-ALL, the specific chromosome gains with prognostic value in HHD-B-ALL remain controversial, and the current knowledge about the hierarchy of chromosome gains, clonal heterogeneity and chromosomal instability in HHD-B-ALL remains very limited. We applied automated sequential-iFISH coupled with single-cell computational modeling to identify the specific chromosomal gains of the eight typically gained chromosomes in a large cohort of 72 primary diagnostic (DX, n = 62) and matched relapse (REL, n = 10) samples from HHD-B-ALL patients with either favorable or unfavorable clinical outcome in order to characterize the clonal heterogeneity, specific chromosome gains and clonal evolution. Our data show a high degree of clonal heterogeneity and a hierarchical order of chromosome gains in DX samples of HHD-B-ALL. The rates of specific chromosome gains and clonal heterogeneity found in DX samples differ between HHD-B-ALL patients with favorable or unfavorable clinical outcome. In fact, our comprehensive analyses at DX using a computationally defined risk predictor revealed low levels of trisomies +18+10 and low levels of clonal heterogeneity as robust relapse risk factors in minimal residual disease (MRD)-negative childhood HHD-B-ALL patients: relapse-free survival beyond 5 years: 22.1% versus 87.9%, P < 0.0001 and 33.3% versus 80%, P < 0.0001, respectively. Moreover, longitudinal analysis of matched DX-REL HHD-B-ALL samples revealed distinct patterns of clonal evolution at relapse. Our study offers a reliable prognostic sub-stratification of pediatric MRD-negative HHD-B-ALL patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The insecticides permethrin and chlorpyrifos show limited genotoxicity and no leukemogenic potential in human and murine hematopoietic stem progenitor cells

  • Rodriguez-Cortez, Virginia C.
  • Navarrete-Meneses, Maria Pilar
  • Molina, Oscar|||0000-0001-7585-4519
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • González, Jéssica
  • Romecín, Paola Alejandra|||0000-0001-6890-5883
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Roca Ho, Heleia|||0000-0001-7324-5234
  • Vinyoles, Meritxell|||0000-0003-1906-4701
  • Kowarz, Eric
  • Marin, Pedro
  • Rodriguez-Perales, Sandra|||0000-0001-7221-3636
  • Gomez-Marin, Carlos
  • Perez-Vera, Patricia
  • Cortes-Ledesma, Felipe
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Terron, Andrea
  • Bueno, Clara|||0000-0003-1442-6216
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CD34 + CD19 - CD22 + B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

  • Bueno, Clara|||0000-0003-1442-6216
  • Barrera, Susana
  • Bataller, Alex|||0000-0002-6085-2745
  • Ortiz-Maldonado, Valentín|||0000-0003-4699-6862
  • Elliot, Natalina
  • O'Byrne, Sorcha|||0000-0002-3116-1646
  • Wang, Guanlin
  • Rovira, Montse
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Trincado Alonso, Juan Luis, 1987-|||0000-0001-5363-3774
  • González-González, María|||0000-0001-8115-1086
  • Morgades, Mireia|||0000-0003-0295-2534
  • Sorigue, Marc|||0000-0002-0587-591X
  • Bárcena, Paloma
  • Zanetti, S. R.|||0000-0002-9052-8751
  • Torrebadell, Montse|||0000-0002-0027-3215
  • Vega-Garcia, Nerea
  • Rives, Susana|||0000-0002-5658-1831
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • Sole, F.|||0000-0002-3251-2161
  • Mead, Adam J.|||0000-0001-8522-1002
  • Roberts, Irene|||0000-0002-6094-6397
  • Thongjuea, Supat|||0000-0002-9129-4694
  • Psaila, Bethan|||0000-0001-8198-9663
  • Juan, Manel|||0000-0002-3064-1648
  • Delgado, Julio|||0000-0002-5157-4376
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Orfao, Alberto|||0000-0002-0007-7230
  • Roy, Anindita
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Three article in this issue present preclinical data aimed at improving immunotherapeutic approaches for relapsed B- and T-cell acute lymphoblastic leukemia (T-ALL). Chimeric antigen receptor T (CAR-T) cell therapy directed against relapsed T-ALL is hampered by difficulty in identifying a target antigen that is not also expressed on healthy T cells, risking "fratricide" with T-cell aplasia and loss of the CAR-T cells. Maciocia and colleagues identify CCR9 as an antigen expressed on.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

TIM3, a human acute myeloid leukemia stem cell marker, does not enrich for leukemia-initiating stem cells in B-cell acute lymphoblastic leukemia

  • Bueno, Clara|||0000-0003-1442-6216
  • Martínez, Alba
  • Romecín, Paola Alejandra|||0000-0001-6890-5883
  • Zanetti, S. R.|||0000-0002-9052-8751
  • Tirtakusuma, Ricky
  • Genesca, Eulalia
  • Camós, Mireia|||0000-0003-3658-7942
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Anguita, Eduardo|||0000-0003-1386-4943
  • Ballerini, Paola
  • Locatelli, Franco|||0000-0002-7976-3654
  • Fuster, José Luis|||0000-0002-4881-9440
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Hyaluronic acid-GPRC5C signalling promotes dormancy in haematopoietic stem cells

  • Zhang, Yu Wei
  • Mess, Julian
  • Aizarani, Nadim
  • Mishra, Pankaj
  • Johnson, Carys
  • Romero-Mulero, Mari Carmen|||0000-0002-6705-7613
  • Rettkowski, Jasmin
  • Schönberger, Katharina
  • Obier, Nadine
  • Jäcklein, Karin
  • Woessner, Nadine M.
  • Lalioti, Maria Eleni
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • Sikora, Katarzyna
  • Wäsch, Ralph
  • Lehnertz, Bernhard
  • Sauvageau, Guy
  • Manke, Thomas
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Walter, Sebastian Gottfried
  • Minguet, Susana
  • Laurenti, Elisa
  • Günther, Stefan
  • Grün, Dominic
  • Cabezas-Wallscheid, Nina
Bone marrow haematopoietic stem cells (HSCs) are vital for lifelong maintenance of healthy haematopoiesis. In inbred mice housed in gnotobiotic facilities, the top of the haematopoietic hierarchy is occupied by dormant HSCs, which reversibly exit quiescence during stress. Whether HSC dormancy exists in humans remains debatable. Here, using single-cell RNA sequencing, we show a continuous landscape of highly purified human bone marrow HSCs displaying varying degrees of dormancy. We identify the orphan receptor GPRC5C, which enriches for dormant human HSCs. GPRC5C is also essential for HSC function, as demonstrated by genetic loss- and gain-of-function analyses. Through structural modelling and biochemical assays, we show that hyaluronic acid, a bone marrow extracellular matrix component, preserves dormancy through GPRC5C. We identify the hyaluronic acid-GPRC5C signalling axis controlling the state of dormancy in mouse and human HSCs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells

  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • Trincado Alonso, Juan Luis, 1987-|||0000-0001-5363-3774
  • Vinyoles, Meritxell|||0000-0003-1906-4701
  • Closa, Adria|||0000-0002-9302-337X
  • Martínez Moreno, Alba|||0000-0001-7514-260X
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Molina, Oscar|||0000-0001-7585-4519
  • Rodríguez-Cortez, Virginia Carolina|||0000-0002-0853-247X
  • Ximeno-Parpal, Pau|||0000-0003-1814-9607
  • Fernández Fuentes, Narcís|||0000-0002-6421-1080
  • Petazzi, Paolo|||0000-0002-1036-2895
  • Beneyto Calabuig, Sergi|||0000-0003-3773-8239
  • Velten, Lars
  • Romecín, Paola Alejandra|||0000-0001-6890-5883
  • Casquero, Raquel
  • Abollo-Jiménez, Fernando
  • de la Guardia, Rafael D.
  • Lorden, Patricia
  • Bataller, Alex|||0000-0002-6085-2745
  • Lapillonne, Hélène|||0000-0002-6900-8313
  • Stam, Ronald W.
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Torrebadell, Montserrat
  • Fuster, José Luis|||0000-0002-4881-9440
  • Bueno, Clara|||0000-0003-1442-6216
  • Sarry, Jean Emmanuel
  • Eyras, Eduardo|||0000-0003-0793-6218
  • Heyn, Holger|||0000-0002-3276-1889
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Relapse remains a major challenge in the clinical management of acute myeloid leukemia (AML) and is driven by rare therapy-resistant leukemia stem cells (LSCs) that reside in specific bone marrow niches. Hypoxia signaling maintains cells in a quiescent and metabolically relaxed state, desensitizing them to chemotherapy. This suggests the hypothesis that hypoxia contributes to the chemoresistance of AML-LSCs and may represent a therapeutic target to sensitize AML-LSCs to chemotherapy. Here, we identify HIF and HIF specific AML subgroups (inv(16)/t(8;21) and MLLr, respectively) and provide a comprehensive single-cell expression atlas of 119,000 AML cells and AML-LSCs in paired diagnostic-relapse samples from these molecular subgroups. The HIF/hypoxia pathway signature is attenuated in AML-LSCs compared with more differentiated AML cells but is more expressed than in healthy hematopoietic cells. Importantly, chemical inhibition of HIF cooperates with standard-of-care chemotherapy to impair AML growth and to substantially eliminate AML-LSCs in vitro and in vivo. These findings support the HIF pathway in the stem cell-driven drug resistance of AML and unravel avenues for combinatorial targeted and chemotherapy-based approaches to specifically eliminate AML-LSCs.